Huntingtin's spherical solenoid structure enables polyglutamine tract-dependent modulation of its structure and function

  1. Ravi Vijayvargia
  2. Raquel Epand
  3. Alexander Leitner
  4. Tae-Yang Jung
  5. Baehyun Shin
  6. Roy Jung
  7. Alejandro Lloret
  8. Randy Singh Atwal
  9. Hyeongseok Lee
  10. Jong-Min Lee
  11. Ruedi Aebersold
  12. Hans Hebert
  13. Ji-Joon Song
  14. Ihn Sik Seong  Is a corresponding author
  1. The Maharaja Sayajirao University of Baroda, India
  2. McMaster University, Canada
  3. Eidgenössische Technische Hochschule Zürich, Switzerland
  4. Korea Advanced Institute of Science and Technology, Republic of Korea
  5. Massachusetts General Hospital, United States
  6. Universidad Autónoma de Querétaro, Mexico
  7. Karolinska Institute, Sweden

Abstract

The polyglutamine expansion in huntingtin protein causes Huntington's disease. Here, we investigated structural and biochemical properties of huntingtin and the effect of the polyglutamine expansion using various biophysical experiments including circular dichroism, single-particle electron microscopy and cross-linking mass spectrometry. Huntingtin is likely composed of five distinct domains and adopts a spherical α-helical solenoid where the amino-terminal and carboxyl-terminal regions fold to contain a circumscribed central cavity. Interestingly we showed that the polyglutamine expansion increases α-helical properties of huntingtin and affects the intramolecular interactions among the domains. Our work delineates the structural characteristics of full-length huntingtin, which are affected by the polyglutamine expansion, and provides an elegant solution to the apparent conundrum of how the extreme amino-terminal polyglutamine tract confers a novel property on huntingtin, causing the disease.

Article and author information

Author details

  1. Ravi Vijayvargia

    Department of Biochemistry, The Maharaja Sayajirao University of Baroda, Vadodara, India
    Competing interests
    The authors declare that no competing interests exist.
  2. Raquel Epand

    Biochemical ad Biomedical Sciences, McMaster University, Hamilton, Canada
    Competing interests
    The authors declare that no competing interests exist.
  3. Alexander Leitner

    Department of Biology, Institute of Molecular Systems Biology, Eidgenössische Technische Hochschule Zürich, Zurich, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  4. Tae-Yang Jung

    Department of Biological Sciences, Cancer Metastasis Control Center, KAIST Institute for the BioCentury, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea
    Competing interests
    The authors declare that no competing interests exist.
  5. Baehyun Shin

    Center for Human Genetic Research, Massachusetts General Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Roy Jung

    Center for Human Genetic Research, Massachusetts General Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Alejandro Lloret

    Facultad de Medicina, Universidad Autónoma de Querétaro, Santiago de Querétaro, Mexico
    Competing interests
    The authors declare that no competing interests exist.
  8. Randy Singh Atwal

    Center for Human Genetic Research, Massachusetts General Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Hyeongseok Lee

    Department of Biological Sciences, Cancer Metastasis Control Center, KAIST Institute for the BioCentury, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea
    Competing interests
    The authors declare that no competing interests exist.
  10. Jong-Min Lee

    Center for Human Genetic Research, Massachusetts General Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Ruedi Aebersold

    Department of Biology, Institute of Molecular Systems Biology, Eidgenössische Technische Hochschule Zürich, Zurich, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  12. Hans Hebert

    Department of Biosciences and Nutrition, Karolinska Institute, Solna, Sweden
    Competing interests
    The authors declare that no competing interests exist.
  13. Ji-Joon Song

    Department of Biological Sciences, Cancer Metastasis Control Center, KAIST Institute for the BioCentury, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea
    Competing interests
    The authors declare that no competing interests exist.
  14. Ihn Sik Seong

    Center for Human Genetic Research, Massachusetts General Hospital, Boston, United States
    For correspondence
    iseong@mgh.harvard.edu
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Bart De Strooper, VIB Center for the Biology of Disease, KU Leuven, Belgium

Version history

  1. Received: August 29, 2015
  2. Accepted: March 13, 2016
  3. Accepted Manuscript published: March 22, 2016 (version 1)
  4. Version of Record published: April 5, 2016 (version 2)

Copyright

© 2016, Vijayvargia et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,591
    views
  • 959
    downloads
  • 52
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ravi Vijayvargia
  2. Raquel Epand
  3. Alexander Leitner
  4. Tae-Yang Jung
  5. Baehyun Shin
  6. Roy Jung
  7. Alejandro Lloret
  8. Randy Singh Atwal
  9. Hyeongseok Lee
  10. Jong-Min Lee
  11. Ruedi Aebersold
  12. Hans Hebert
  13. Ji-Joon Song
  14. Ihn Sik Seong
(2016)
Huntingtin's spherical solenoid structure enables polyglutamine tract-dependent modulation of its structure and function
eLife 5:e11184.
https://doi.org/10.7554/eLife.11184

Share this article

https://doi.org/10.7554/eLife.11184

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Damien M Rasmussen, Manny M Semonis ... Nicholas M Levinson
    Research Article

    The type II class of RAF inhibitors currently in clinical trials paradoxically activate BRAF at subsaturating concentrations. Activation is mediated by induction of BRAF dimers, but why activation rather than inhibition occurs remains unclear. Using biophysical methods tracking BRAF dimerization and conformation, we built an allosteric model of inhibitor-induced dimerization that resolves the allosteric contributions of inhibitor binding to the two active sites of the dimer, revealing key differences between type I and type II RAF inhibitors. For type II inhibitors the allosteric coupling between inhibitor binding and BRAF dimerization is distributed asymmetrically across the two dimer binding sites, with binding to the first site dominating the allostery. This asymmetry results in efficient and selective induction of dimers with one inhibited and one catalytically active subunit. Our allosteric models quantitatively account for paradoxical activation data measured for 11 RAF inhibitors. Unlike type II inhibitors, type I inhibitors lack allosteric asymmetry and do not activate BRAF homodimers. Finally, NMR data reveal that BRAF homodimers are dynamically asymmetric with only one of the subunits locked in the active αC-in state. This provides a structural mechanism for how binding of only a single αC-in inhibitor molecule can induce potent BRAF dimerization and activation.

    1. Structural Biology and Molecular Biophysics
    Nicholas James Ose, Paul Campitelli ... Sefika Banu Ozkan
    Research Article

    We integrate evolutionary predictions based on the neutral theory of molecular evolution with protein dynamics to generate mechanistic insight into the molecular adaptations of the SARS-COV-2 spike (S) protein. With this approach, we first identified candidate adaptive polymorphisms (CAPs) of the SARS-CoV-2 S protein and assessed the impact of these CAPs through dynamics analysis. Not only have we found that CAPs frequently overlap with well-known functional sites, but also, using several different dynamics-based metrics, we reveal the critical allosteric interplay between SARS-CoV-2 CAPs and the S protein binding sites with the human ACE2 (hACE2) protein. CAPs interact far differently with the hACE2 binding site residues in the open conformation of the S protein compared to the closed form. In particular, the CAP sites control the dynamics of binding residues in the open state, suggesting an allosteric control of hACE2 binding. We also explored the characteristic mutations of different SARS-CoV-2 strains to find dynamic hallmarks and potential effects of future mutations. Our analyses reveal that Delta strain-specific variants have non-additive (i.e., epistatic) interactions with CAP sites, whereas the less pathogenic Omicron strains have mostly additive mutations. Finally, our dynamics-based analysis suggests that the novel mutations observed in the Omicron strain epistatically interact with the CAP sites to help escape antibody binding.